Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation

v3.23.1
Stock-Based Compensation
12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
Stock Incentive Plan
On October 31, 2014, the Board approved the Company’s 2014 Omnibus Incentive Plan (the “2014 Plan”). The 2014 Plan authorizes the issuance of awards including stock options, stock appreciation rights, restricted stock, stock units and performance units to employees, directors, and consultants of the Company.
On June 14, 2022, in connection with the Acquisition, the Board approved the 2014 Amended and Restated Omnibus Incentive Plan (the “2014 Amended and Restated Plan”) which replaced the 2014 Plan in its entirety. The 2014 Amended and Restated Plan, among other things, fixed the number of shares that can be issued under the plan to 91,219,570, provided that each January 1 beginning in 2023 and ending on (and including) January 1, 2032 the number of shares will increase by 5% of the outstanding shares of Common Stock as of the prior December 31, unless the Board of Directors of the Company decides to a lesser increase.
On September 30, 2022, the Amended and Restated 2014 Plan was approved by the shareholders. The 2014 Amended and Restated Plan authorizes the issuance of awards including stock options, stock appreciation rights, restricted stock, stock units and performance units to employees, directors, and consultants of the Company. The Company has reserved shares for issuance under our equity incentive plan upon share option exercise. As of December 31, 2022, the Company had 42,274,757 shares available for future grant under the 2014 Plan.
As of December 31, 2022, the shares available for future grant under the 2014 Amended and Restated Plan are as follows:
Shares Available for Grant
Available as of December 31, 2021 14,132,929 
Share pool increase 35,731,891 
Forfeited 3,810,345 
Cancelled 1,232,218 
Granted (12,632,626)
Available as of December 31, 2022 42,274,757 
Stock Options
Options granted under the 2014 Amended and Restated Plan expire no later than ten years from the date of grant. Options granted under the 2014 Amended and Restated Plan may be either incentive or non-qualified stock options. For incentive and non-qualified stock option grants, the option price shall be at least 100% of the fair value on the date of grants, as determined by the Company’s Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant.
Options granted under the 2014 Amended and Restated Plan may be immediately exercisable if permitted in the specific grant approved by the Board of Directors and, if exercised early may be subject to repurchase provisions. The shares issued generally vest over a period of one to four years from the date of grant.
The following is a summary of option activities under the Company’s 2014 Amended and Restated Plan for the year ended December 31, 2022:
Number of
Shares
Weighted
Average
Exercise Price
Weighted
Average Remaining
Contractual
Term (Years)
Aggregate
Intrinsic
Value*
Outstanding, December 31, 2021 35,405,000  $ 0.07  9.08 $ 134,750 
Granted (1)
12,632,626  0.49 
Forfeited (1,232,218) 0.47 
Cancelled (3,810,346) 0.07 
Outstanding, December 31, 2022 42,995,062  $ 0.18  7.14 $  
Exercisable, December 31, 2022 25,441,484  $ 0.08  7.8 $  
Vested and expected to vest, December 31, 2022 42,995,062  $ 0.18  7.14 $  
*The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company’s stock exceeded the exercise price of the stock options at December 31, 2022 for those stock options for which the quoted market price was in excess of the exercise price ("in-the-money options").
(1) Includes 8,282,626 rollover options issued under the 2014 Plan related to the Acquisition. Upon the closing of the Acquisition, the entire fair value of the EHT rollover options was allocated to the purchase consideration. As a result the assumptions below exclude the EHT rollover options (See Note 3)
During the years ended December 31, 2022 and 2021, the Company received $— and $4,783 gross proceeds from the exercise of stock options.
The weighted-average grant-date fair value of stock options granted for the years ended December 31, 2022 and 2021, excluding EHT rollover options issued related to the Acquisition, was $0.04 and $0.07, respectively. The total fair value of the stock options that vested during the years ended December 31, 2022 and 2021 was $466,263 and $316,929, respectively.
The fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model under the following assumptions:
Year Ended December 31,
2022 2021
Dividend yield 0.00  % 0.00  %
Risk-free interest rate
2.89-3.60%
0.01-1.11%
Expected term (years)
5.00-6.08
5.27-6.13
Volatility
126.27-132.58%
119.10-138.00%
In connection with the termination of Dr. Avtar Dhillon's Independent Contractor Agreement on October 14, 2021 (Note 11), the Company modified Dr. Dhillon's option awards to accelerate the vesting of 1,650,000 unvested stock options and, extend the post-termination exercise period from 30 days to five years for all of his outstanding awards. The approval of the modification and receipt of notice to terminate the Independent Contractor Agreement on September 14, 2021, resulted in the recognition of $309,487 in stock compensation expense for the year ended December 31, 2021.
In connection with the Acquisition the Company issued a total of 8,282,626 stock options to EHT option holders on November 10, 2022 (Note 3). The exercise price and rollover option shares were adjusted by the Exchange Ratio at the Acquisition date and retain the vest periods as originally issued.
Stock Option Awards with Performance and Other Conditions
During the year ended December 31, 2022, the Company granted 4,000,000 stock options with an exercise price of $0.04 which include a combination of performance vesting conditions and other vesting conditions pursuant to a consulting agreement entered with Mr. Jim Heppell, a former director of Skye and related party of the Company (Note 13). The vesting conditions of the stock option award provide that 50% of the options are vested upon grant and the remaining 50% will vest upon the sale of a real estate asset held by EHT at an amount greater than or equal to an amount specified in the agreement. None of the options were exercisable until the Acquisition was consummated on November 10, 2022, (Note 3). The conditions related to the sale of EHT's real estate are considered other conditions and the condition related to the closing of the Acquisition is considered a performance condition. When a performance condition is deemed to be probable of achievement, time-based vesting and recognition of stock-based compensation expense commences.
As a result, no share-based compensation expense will be recognized for these stock options until the performance condition is considered to be probable. As of December 31, 2022, the Company has determined that the sale of the real estate asset is not deemed probable, as the consummation of the sale is not solely within the control of the Company.
As of December 31, 2022, the Company has included $73,368 related to the first tranche of these awards in total stock-based compensation expense below. The Company has evaluated the second tranche and has determined that due to the other conditions contained in these awards that they will be recorded as liability options once the Acquisition is deemed probable and will be remeasured through their settlement date or cancellation (Note 15).
Restricted Stock Units
On December 14, 2021, the Company granted restricted stock units (“RSUs”) to its executive management team. The RSUs cliff vest 33% per year on the anniversary of the grant date over a three year period.
The following is a summary of restricted stock unit activity during the year ended December 31, 2022:
Number of
Shares
Weighted Average Grant Date Fair Value
Unvested, December 31, 2021 4,000,000  $ 0.06 
Granted —  — 
Released (1,333,333) 0.06 
Unvested, December 31, 2022 2,666,667  $ 0.06 

Awards Granted Outside the 2014 Amended and Restated Plan
During the year ended December 31, 2021, the Company granted 1,200,000 and 300,000 restricted shares of common stock to a non-employee consultant for investor relations services under two successive six month service contracts. Half of the shares will be issued within the first month of entering each service contract and the remaining half will be issued within thirty days from contract completion.
The following is a summary of restricted stock activity outside of the 2014 Amended and Restated Plan during the year ended December 31, 2022:
Number of Shares Weighted Average Grant Date Fair Value
Unvested, December 31, 2021 150,000  $ 0.13 
Granted —  — 
Released (150,000) 0.13 
*Unvested, December 31, 2022   $  
Stock-Based Compensation Expense
The Company recognizes stock-based compensation expense using the straight-line method over the requisite service period. The Company recognized stock-based compensation expense, including compensation expense for warrants with vesting provisions issued to a service provider (Note 6), and the RSUs discussed above, in its Consolidated Statements of Operations as follows:
Year Ended
December 31,
2022 2021
Research and development $ 77,965  $ 59,653 
General and administrative 530,234  809,553 
$ 608,199  $ 869,206 
The total amount of unrecognized compensation cost was $964,853 as of December 31, 2022. This amount will be recognized over a weighted-average period of 1.81 years.
2022 Employee Stock Purchase Plan
In June 2022, the Company's board of directors approved the 2022 Employee Stock Purchase Plan (the "ESPP"). Under which the Company will offer eligible employees the option to purchase common stock at a 15% discount to the lower of the market value of the stock at the beginning or end of each participation period under the terms of the ESPP. Total individual purchases in any year are limited to 15% of compensation. The ESPP was approved by the Company's stockholders on September 30, 2022. As of December 31, 2022, no shares were issued under the ESPP.